THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER Drug Patent Profile

When do Theophylline And Dextrose 5% In Plastic Container patents expire, and what generic alternatives are available?

Theophylline And Dextrose 5% In Plastic Container is a drug marketed by Baxter Hlthcare and is included in one NDA.

The generic ingredient in THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER is theophylline. There are thirty-six drug master file entries for this compound. Twenty-six suppliers are listed for this compound. Additional details are available on the theophylline profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Theophylline And Dextrose 5% In Plastic Container

A generic version of THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER was approved as theophylline by RHODES PHARMS on September 1^st, 1982.

Summary for THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	31
Clinical Trials:	122
DailyMed Link:	THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER at DailyMed

Recent Clinical Trials for THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
University of Nebraska	PHASE1
Minia University	EARLY_PHASE1
Assiut University	PHASE1

See all THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER clinical trials

US Patents and Regulatory Information for THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Baxter Hlthcare	THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER	theophylline	INJECTABLE;INJECTION	018649-007	Jul 26, 1982		DISCN	No	No
Baxter Hlthcare	THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER	theophylline	INJECTABLE;INJECTION	018649-005	Jul 26, 1982		DISCN	No	No
Baxter Hlthcare	THEOPHYLLINE AND DEXTROSE 5% IN PLASTIC CONTAINER	theophylline	INJECTABLE;INJECTION	018649-003	Jul 26, 1982		DISCN	No	No

Last updated: February 10, 2026

Market Overview and Financial Trajectory of Theophylline and Dextrose 5% in Plastic Containers

Theophylline and dextrose 5% in plastic containers are used mainly in hospital settings for respiratory therapy and intravenous nutrition, respectively. The market is characterized by steady demand driven by increases in chronic respiratory diseases and hospital admissions. However, the landscape faces patent expiry, competition from generics, and regulatory pressures.

Market Size and Growth Drivers

Global Market Valuation and Trends

The global intravenous (IV) drug market is projected to grow from USD 17.4 billion in 2022 to USD 26.4 billion by 2030, at a CAGR of 5.4% (source [1]). While specific data for theophylline and dextrose solutions is limited, these products constitute a subset of the IV and respiratory segments.

The demand for theophylline has declined in some markets due to the availability of newer bronchodilators but remains relevant in regions with limited access to advanced therapies. Dextrose 5% solutions are widely used for hydration and delivery of medications; their production is tied to hospital procurement cycles.

Key Growth Drivers

• Rising incidence of chronic obstructive pulmonary disease (COPD) and asthma increases the need for theophylline therapy.
• Growth in hospital admissions and need for IV nutrition fuels demand for dextrose solutions.
• Increased adoption of home healthcare and outpatient infusion services.
• Expanding healthcare infrastructure in emerging markets.

Regional Market Dynamics

• North America dominates due to high prevalence of respiratory diseases and advanced healthcare infrastructure.
• Europe shows moderate growth, driven by aging populations.
• Asia-Pacific exhibits the highest growth potential, projected to grow at a CAGR exceeding 6% owing to expanding healthcare access and infrastructure.

Competitive Landscape and Patent Status

Product Approvals and Manufacturing

• Theophylline and dextrose 5% in plastic containers are often produced as off-patent generics.
• Multiple pharmaceutical companies hold manufacturing licenses for these solutions, with key players including Baxter International, Fresenius Kabi, and local generic producers.
• Regulatory agencies like the FDA (U.S.) and EMA (Europe) require compliance with USP and Ph. Eur. standards.

Market Entry Barriers

• High compliance costs for sterile manufacturing.
• Quality assurance for intravenous solutions.
• Existing agreements with healthcare providers and procurement contracts.

Pricing Trends and Revenue Projections

Parameter	Current Price Range (USD per liter)	Notes
Theophylline solution	1.50 – 3.00	Slight variation based on manufacturer and region.
Dextrose 5% solution	0.50 – 1.00	Lower pricing due to high volume production.

Pricing pressure from generics and tender-based procurement leads to margins narrowing. Revenues are heavily dependent on procurement volume, hospital contracts, and regional demand.

Forecasting indicates that active markets could generate combined revenues of USD 1.2 billion annually by 2026, with growth primarily driven by emerging markets. The stable, essential nature of these solutions implies consistent revenues but limited premium potential.

Regulatory and Market Access Risks

• Stringent quality standards increase manufacturing costs.
• Regional regulatory differences may delay market access or require formulary negotiations.
• Potential shifts towards newer therapies could reduce demand over the next decade.

Key Takeaways

• The market for theophylline and dextrose 5% solutions in plastic containers is stable and primarily institutional.
• Growth is driven by rising hospital admissions and disease prevalence but offset by competition from newer drugs and generics.
• Regional variability affects pricing and market size, with emerging markets showing strong growth prospects.
• Limited innovation and patent expiration constrain revenue growth; reliance on cost efficiencies and supply chain optimization is critical.

FAQs

1. What are the main applications for theophylline and dextrose 5% solutions?

Theophylline is used for respiratory conditions like asthma and COPD, while dextrose 5% solutions provide hydration and vehicle for medications.

2. How does patent expiry affect the market?

Patent expiry leads to increased generic competition, resulting in lower prices and margins, but also wider accessibility and increased market penetration.

3. Which regions present the most growth opportunities?

Emerging markets in Asia-Pacific and Latin America are expanding rapidly due to increased healthcare infrastructure and hospital capacity.

4. What are the primary risks for investors?

Regulatory changes, reduced demand from newer therapies, and price pressures due to generic competition.

5. How might technological innovation impact this market?

Development of alternative formulations or delivery methods could threaten existing products; however, no significant product innovations are expected in the near term.

References

[1] MarketsandMarkets. Intravenous (IV) Therapy Market Research Report, 2022.